Company news

Orthocell Ltd news in 2025

Orthocell Ltd's news releases, calls and decks from 2025, newest first.

View company

Orthocell Hits US Milestone - 100 Remplir Units Sold.

December 17, 2025

Remplir Regulatory Application for US$750m EU-UK Market

December 14, 2025

First Commercial Sales of Remplir Achieved in Hong Kong

December 9, 2025

Remplir™ Nerve Sparing Prostate Cancer Surgery Commercial Opportunity Gathers Momentum with ~100 Surgeries Now Performed with Multiple Surgeons Nationwide

November 20, 2025

Remplir gains momentum in nerve-sparing prostate surgery

November 19, 2025

2nd Distributor in Canada, Entire $75m Market Now Covered

November 4, 2025

Remplir Launches in Hong Kong with First Surgical Case

November 2, 2025

HK Distributor Signed as Remplir Expands in the Asian Market

October 28, 2025

OCC Secures Rights to High-Value Bone Regeneration Tech

October 19, 2025

$30m Placement Sees Orthocell Positioned for Rapid Growth

October 16, 2025

Trading Halt

October 14, 2025

Another Record Revenue Quarter for Orthocell

October 1, 2025

First Distributor signed for Remplir in $75m Canadian Market

September 29, 2025

Globally Significant Opportunity Emerges as Remplir™ is used in Nerve-Sparing Prostate Cancer Surgery

September 16, 2025

Remplir Use in Prostate Surgery Signals Global Opportunity

September 15, 2025

Remplir™ Study Delivers Compelling 81% Success Rate

September 8, 2025

Compelling 81% Success Rate for Remplir

September 7, 2025

Appendix 4E & Annual Report

August 29, 2025

Orthocell Announces First US Remplir Sales Revenue

July 9, 2025

Record Revenue of $2.73m in June 25 Quarter up 22.8% QoQ

June 30, 2025

First Surgical Use of Remplir in US$1.6 Billion US Market

June 26, 2025

Compelling Data Highlights Remplir Competitive Advantage

June 18, 2025

Remplir Approved to Commence Sales in the Hong Kong Market

May 11, 2025

12 Distributors Signed for Remplir Covering 21 States in US

May 8, 2025

Remplir Approved to Commence Sales in US$75m Canadian Market

April 29, 2025

Replacement Trading Halt

April 29, 2025

Pause in Trading

April 29, 2025

Remplir Approved to Commence Sales in US$84M Thai Market

April 27, 2025

First US Distributors Signed for Remplirs US$1.6B market

April 23, 2025

Regulatory Approval for Striate in US$65M Brazilian Market

April 8, 2025

Remplir Cleared to Commence Sales in US$1.6B US Market

April 3, 2025

Investor Presentation - US FDA 510(k) Clearance for Remplir

April 3, 2025

First Sales of Striate in Germany, Austria & Swiss Region

March 25, 2025

Regulatory approval to commence Striate sales in Singapore

March 17, 2025

S&P DJI Announces March 2025 Quarterly Rebalance

March 7, 2025

Orthocell Receives $3.18 million R&D Tax Refund

January 19, 2025

Third Consecutive Quarter of Record Revenue for Orthocell

January 7, 2025

Decks in 2025